CNC

Quick Update for Centene (CNC) Investors

Shares of Health Care sector company Centene moved -1.1% today, and are now trading at a price of $74.03. The large-cap stock's daily volume was 2,218,762 compared to its average volume of 3,237,234. The S&P 500 index returned a -1.0% performance.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company is based in Saint Louis and has 74,300 full time employees. Its market capitalization is $39,546,900,480.

15 analysts are following Centene and have set target prices ranging from $72.0 to $110.0 per share. On average, they have given the company a rating of buy. At today's prices, CNC is trading -11.37% away from its average analyst target price of $83.53 per share.

Over the last year, CNC shares have gone down by -14.0%, which represents a difference of -29.0% when compared to the S&P 500. The stock's 52 week high is $87.79 per share and its 52 week low is $60.83. With average free cash flows of $3.32 Billion that have been growing at an average rate of 46.2% over the last 6 years, Centene declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 6,260,000 809,000 5,451,000 3.69
2022 6,261,000 1,004,000 5,257,000 59.54
2021 4,205,000 910,000 3,295,000 -28.9
2020 5,503,000 869,000 4,634,000 515.41
2019 1,483,000 730,000 753,000 34.7
2018 1,234,000 675,000 559,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS